Precision Medicine Enablement via Advanced Diagnostics
Advances in diagnostics—Including pharmacogenomics, emerging tumor markers, the importance of individual genetic variability to risk, understanding the influence of the microbiome, complimentary and companion diagnostics—are rapidly changing our approach to medication therapy from a “shot gun,” trial-and error approach to personalized/precision medication and gene therapy choices.
Chair: Steve Goldberg, MD, MBA, Vice President, Medical Affairs, Population Health and Chief Health Officer, Health & Wellness, Quest Diagnostics
Co-Lead: Micheal Tobin, M. Arch, Director Healthcare Policy and Advocacy, Strategic Customer Group, Johnson & Johnson
Co-Lead: Brian Caveney, MD, JD, MPH, Enterprise-Wide Chief Medical Officer, LabCorp
GTMRx Institute workgroups are the way we’re moving the ball forward. Are you interested in following a workgroup? We welcome members to play a role, so please complete the form below if you would like to follow our work. We also encourage you to be a member of the GTMRx Institute.